With the rapid development of proteomics technology, protein profiling analysis characterized by "trapped ion mobility spectrometry (TIMS)" has given rise to a new technology called "4D proteomics". It has demonstrated promising development potential and remarkable versatility across various domains, including basic medical research, translational medicine, and clinical proteomics.
PTM BIO has been a trailblazer in "4D proteomics" analysis since 2019 and is on track to achieve "full coverage" of 4D proteomic analysis types by 2021. Within a span of just two years, from its inception to maturity, PTM Bio's 4D proteomics technology has processed over 10,000 high-performance detection samples, earning high recognition from customers and the industry alike. This has firmly cemented PTM BIO's leading position in the industry.
What kind of magic power does PTM Bio 4D proteomics possess?
01｜Be the first to usher in a new era of "4D proteomics"
As a leading company in the field of proteomics in China, PTM BIO took the initiative to introduce and establish a "4D proteomics platform" in the domestic industry in May 2019. PTM BIO has developed a new generation of 4D proteomics technology that significantly improves the performance of analysis. Moreover, PTM BIO has organized and conducted the first advanced seminar on 4D proteomics and bioinformatics in China, thereby advancing "4D proteomics" from a mere concept to its application across multiple dimensions such as hardware equipment and software methods. These efforts have ushered in a new era of "4D proteomics".
▲ PTM BIO took the lead in introducing and building a 4D proteomics platform in the domestic industry
02｜Large-scale, high-performance "4D proteomics" mass spectrometer cluster
PTM BIO has established a large-scale, high-resolution mass spectrometer cluster to conduct comprehensive "4D proteomics" analysis in multiple directions. The platform features a timsTOF Pro mass spectrometer equipped with an ion mobility separation device and an Exploris 480 high-precision mass spectrometer coupled with a FAIMS ion separation device. With the addition of the first Evosep One high-throughput proteome chromatography system in China, PTM BIO has addressed issues related to low identification depth, low detection throughput, and poor quantitative accuracy often encountered in traditional proteomics research. This allows PTM BIO to provide trace sample, high-depth, high-throughput, and high-sensitivity proteomics analysis for its customers.
▲ PTM BIO “4D proteomics” mass spectrometry platform
03｜Technological transcendence leading to the creation of a series of new "4D proteomics" technologies
PTM BIO has launched a new series of "4D proteomics" technologies, including 4D-LFQ, 4D PTM omics, 4D-DIA, 4D-FFPE, 4D-Blood+, 4D-PRM, and 4D-PRM PTM omics. These technologies have successfully broken through the existing bottleneck of proteomics research. In June 2020, at the American Society for Mass Spectrometry (ASMS) annual meeting, the world's top conference in the field of mass spectrometry, PTM BIO and Bruker jointly released breakthrough results of "4D proteomics" in detecting acetylation and ubiquitination, which received widespread attention and praise.
▲ ASMS2020, PTM BIO and Bruker jointly released the breakthrough results of "4D proteomics"
04｜ Abundant products, providing all types of "4D proteomics" analysis worldwide
As a prominent player in the proteomics industry, PTM BIO is committed to constantly introducing new "4D proteomics" technologies and pushing the boundaries of their application. Currently, PTM BIO provides a wide range of 4D proteomics analysis types, including 4D quantitative proteomics (4D-LFQ, 4D-DIA), 4D clinical trace sample analysis, blood sample 4D-Blood+, and 4D-PRM targeted proteomic validation. Notably, PTM BIO offers 13 types of 4D PTM omics technologies, covering both classic modifications (such as phosphorylation, acetylation, glycosylation, ubiquitination, and methylation) and recently discovered acylation modifications (such as lactylation, succinylation, crotonylation, malonylation, glutarylation, dihydroxyisobutyrylation, trihydroxybutyrylation, and benzoylation). These can all be achieved on the basis of 4D high-depth quantitative analysis, solidifying PTM BIO's leading position in the industry.
05｜Remarkable results, the only company in China that has produced high-level scientific research results of in the field of "4D proteomics".
Within just 2 years, PTM BIO's 4D proteomics platform has conducted quantitative analysis on over 10,000 samples across nearly 1,000 projects, setting new records for in-depth proteomic identification. The technology has been widely applied in research areas such as COVID-19, cardiovascular disease, cancer, plant proteomics, and microbial proteomics. PTM BIO is the only company in China providing customers with "4D proteomics" scientific research results, and has achieved numerous high-level scientific breakthroughs, with two articles selected for brief interpretation.
【1】In November 2020, the research teams from the West China Hospital Sichuan University and the University of Washington jointly published a research result in Circulation Research, which analyzed the important mechanism of NLRP3 inflammasome and mitochondrial dysfunction in the occurrence and development of HFpEF, and deeply analyzed the important role of β-OHB in improving the symptoms of HFpEF (Circulation Research, 2020). PTM BIO provided the 4D acetylation modification omics service and corresponding antibody products.
【2】In September 2020, a joint research team from Tongji Medical College of Huazhong University of Science and Technology and Harvard Medical School published their research results in PNAS. Based on 4D proteomics, the team conducted in-depth proteomic quantification of lung tissue paraffin sections from patients with the new coronavirus pneumonia virus and revealed the mechanism of immune response and inflammatory response regulation, as well as key proteins involved in new coronavirus pneumonia (PNAS, 2020). PTM BIO provided the 4D proteomics service to support the research.
▲ 4D proteomics study of lung tissue samples from patients with novel coronavirus pneumonia [2]
The revolutionary breakthrough in 4D proteomics technology has ushered in a new era of proteomics, and PTM BIO, with its pioneering spirit, is at the forefront of this field. Their "4D proteomics" platform provides trace sample analysis, high-depth quantitative analysis, high-throughput analysis, high-sensitivity detection, and high-accuracy validation, which has opened up endless possibilities for proteomics research. With its commitment to innovation and excellence, PTM BIO is leading the way in the new era of 4D proteomics.
Reference
[1]Deng Y,et al. 2020. Targeting mitochondria-inflammation circuit by β-Hydroxybutyrate Mitigates HFpEF. Cirulation Res.
[2]Meng Wu,et al. 2020. Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. Proc Natl Acad Sci U S A.
